Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ISA 2022 | The role of PET/CT in assessing early treatment response in patients with NDMM

Charalampos Charalampous • 7 Sep 2022
ISA 2022
Multiple Myeloma

Charalampos Charalampous, MD, Mayo Clinic, Rochester, MN, comments on the role of PET/CT in assessing early treatment response in patients with newly diagnosed multiple myeloma (NDMM). In a recent study, it was shown that PET/CT negativity at six months is predictive of better progression-free survival (PFS), time to next treatment, and overall survival (OS). This interview took place at the 2022 International Symposium on Amyloidosis (ISA) held in Heidelberg, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Charalampos Charalampous

5:38
Insights into the pathogenesis of amyloidosis from the proteome of renal amyloid plaques
Charalampos Charalampous • 7 Sep 2022

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals